Protalix BioTherapeutics, Inc. (Amex: PLX) received written notice from the United States Food and Drug Administration (FDA) that it may ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE